Waverly Advisors’s Roivant Sciences ROIV Stock Holding History

Waverly Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$455K	Buy	12,869 +291	+2%	+$8.6K	﹤0.01%	1221
2026 Q1	$348K	Buy	+12,578	New	+$323K	﹤0.01%	1239

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Waverly Advisors's ROIV Position: Q2 2026 in Review

Waverly Advisors increased its Roivant Sciences (ROIV) stake by 2.3% in Q2 2026, buying an estimated $8.6K and bringing the position to 12,869 shares worth $455K. The position accounts for ﹤0.01% of the portfolio, ranked #1221.

Waverly Advisors first reported a position in ROIV in Q1 2026 and has held it in 2 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Waverly Advisors held 12,869 shares of Roivant Sciences worth $455K as of Q2 2026.
Waverly Advisors bought 291 Roivant Sciences shares in Q2 2026, an estimated $8.6K.
Roivant Sciences made up ﹤0.01% of Waverly Advisors's portfolio in Q2 2026, its #1221 holding.
Waverly Advisors first reported a position in Roivant Sciences in Q1 2026 and has held it in 2 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Waverly Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.